BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 16, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Feb. 17, 2021

View Archived Issues
Going public ticker

Humacyte charts IPO via merger with special purpose acquisition company

Humacyte Inc., which develops universally implantable, bioengineered human tissue at commercial scale, has agreed to go public via a merger with Alpha Healthcare Acquisition Corp. (AHAC), a blank-check company led by Rajiv Shukla. Upon closing of the deal, AHAC will be renamed Humacyte Inc. and will be led by Humacyte’s current CEO, Laura Niklason. The combined company’s stock is expected to list on the Nasdaq Capital Market under the ticker symbol HUMA. Read More
FDA-yellow-dice.png

Missing data, lack of operator blinding among issues that sidetrack Lutonix PMA

A U.S. FDA advisory committee voted 14 nays to three ayes that the benefits of the Lutonix 014 drug-coated balloon (DCB) do not outweigh the risks in a panel proceeding peppered by problems with missing data and a lack of operator blinding. The panel widely saw the use of paclitaxel-eluting technologies in other areas of the vasculature as a reassurance that this device might perform as promised, but the outcome nonetheless leaves the sponsor with a new round of negotiations with the FDA as to how to move forward. Read More
3D heart in chest

Rsip Vision develops AI-based coronary artery segmentation tool

HONG KONG – Rsip Vision Ltd. have developed a new coronary artery segmentation tool based on deep learning technology that should allow for faster 3D models of coronary artery anatomy and facilitate precise measurements of artery length and diameter. Read More
Researcher and trial participant

AI-powered brain implant improves post-stroke mobility

Researchers at Thomas Jefferson University have implanted brain electrodes in a patient who suffered a subcortical ischemic stroke more than a year ago to help them overcome abnormal muscle tone and control a robotic arm brace. Artificial intelligence (AI) algorithms interpret neuronal signals recorded by the electrodes into movement of the brace. Read More
Person in hospital scrubs uses Snapshot

Kent’s deal with Net Health to expand Snapshot’s footprint

TORONTO – Think of it. More than 14,000 facilities boasting 98% of the largest hospital chains across the U.S., two-thirds of skilled nursing facilities and hospice organizations and doctors’ offices. It’s that broad customer base Kent Imaging Inc. will have access to following its Jan. 26 agreement with medical software and analytics giant Net Health Inc., helping to expand the footprint of Kent Imaging’s Snapshot device for assessing non-healing wounds, notably those arising from diabetes. Read More

Appointments and advancements for Feb. 17, 2021

New hires and promotions in the med-tech industry, including: Abiomed, Baxter, Biocardia, Day One, Seer, Ultivue. Read More

Financings for Feb. 17, 2021

Med-tech firms raising money in public or private financings, including: Micronoma, Sanara Medtech, Signify Health. Read More

In the clinic for Feb. 17, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anaconda Biomed, Catalyst Orthoscience, Genmark Diagnostics, Vocalis Health. Read More

Other news to note for Feb. 17, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biocorp, Bionic Vision Technologies, Dental Fix Canada, Endra Life Sciences, Ginserv, Goetze Dental, Health2sync, Inspira, Midwest Dental Equipment & Supply, Milestone Scientific, Natera, Personalis, Progenity, Scott’s Dental, Smiths Detection, Socialdiabetes, Teleflex, Theragnostics, Thermo Fisher, Vipergen, Vitalhub. Read More

Regulatory actions for Feb. 17, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Delta International Services & Logistics, Everlywell, Horiba Medical, Thermo Fisher Scientific, Vax-Immune Diagnostics. Read More

Regulatory front for Feb. 17, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: HHS commits more funds for testing, materials to fight pandemic; Medtronic announces recall of Valiant Navion; Florida man pleads guilty in DME fraud. Read More

BioWorld MedTech’s Orthopedics Extra for Feb. 17, 2021

Keeping you up to date on recent developments in orthopedics, including: Radioactive bone cement may be safer in treating spinal tumors; Unlocking the mystery behind skeletal aging; Sweet coating for sour bones. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 15, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 15, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing